A Phase II Study of Delayed Local Treatment for High Risk Neuroblastoma
Phase 2
- Conditions
- High Risk Neuroblastoma
- Registration Number
- JPRN-UMIN000005045
- Lead Sponsor
- Japan Neuroblastoma Study Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 75
Inclusion Criteria
Not provided
Exclusion Criteria
Active double cancer; pregnant or possibly pregnant women and those during breast feeding; patients with psychological disease or symptoms who have difficulty in receiving protocol treatment; patients with disease that may interfere with the protocol treatment
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 3-year progression-free survival rate
- Secondary Outcome Measures
Name Time Method 3-year overall survival rate, the incidence of adverse events, clinical response rate before surgery